Abstract
The increasing danger of methicillin-resistant Staphylococcus aureus (MRSA) and the limited therapeutic options for invasive MRSA infections make an urgent demand for the development of novel anti-MRSA agents. Oxazolidinone derivatives could inhibit protein synthesis by acting on the ribosomal 50S subunit of the bacteria and prevent the formation of a functional 70S initiation complex, so oxazolidinones are a novel class of antimicrobial agents with potential activity against a wide range of clinically significant multidrug-resistant Gram-positive pathogens. However, oxazolidinones such as linezolid are associated with significant adverse events, and myelosuppression represents the main unfavorable side effects. Moreover, MRSA isolates that are resistant to oxazolidinones have already emerged. Hybridization of oxazolidinone with other antibacterial pharmacophores has the potential to interact with multiple targets or to counterbalance the known side effects associated with each pharmacophore. Thus, oxazolidinone-containing hybrids are useful scaffolds for the development of novel anti-MRSA agents. This review covers the recent advances of oxazolidinonecontaining hybrids with anti-MRSA activity developed in the last decade to set up the direction for the design and development of oxazolidinone-containing hybrids with high efficiency and low toxicity.
Keywords: Antibacterial, Hybrid compounds, Methicillin-resistant Staphylococcus aureus, Oxazolidinone, Structure-activity relationships, Gram-positive bacteria.
Current Topics in Medicinal Chemistry
Title:Oxazolidinone-containing Hybrids with Antibacterial Activity against Methicillin-resistant Staphylococcus aureus (MRSA): A Mini-review
Volume: 21 Issue: 27
Author(s): Dan Jiang, Bi Liu and Tao Gao*
Affiliation:
- Hubei Key Laboratory of Radiation Chemistry and Functional Materials, School of Nuclear Technology and Chemistry & Biology, Hubei University of Science and Technology, Xian Ning 437100,China
Keywords: Antibacterial, Hybrid compounds, Methicillin-resistant Staphylococcus aureus, Oxazolidinone, Structure-activity relationships, Gram-positive bacteria.
Abstract: The increasing danger of methicillin-resistant Staphylococcus aureus (MRSA) and the limited therapeutic options for invasive MRSA infections make an urgent demand for the development of novel anti-MRSA agents. Oxazolidinone derivatives could inhibit protein synthesis by acting on the ribosomal 50S subunit of the bacteria and prevent the formation of a functional 70S initiation complex, so oxazolidinones are a novel class of antimicrobial agents with potential activity against a wide range of clinically significant multidrug-resistant Gram-positive pathogens. However, oxazolidinones such as linezolid are associated with significant adverse events, and myelosuppression represents the main unfavorable side effects. Moreover, MRSA isolates that are resistant to oxazolidinones have already emerged. Hybridization of oxazolidinone with other antibacterial pharmacophores has the potential to interact with multiple targets or to counterbalance the known side effects associated with each pharmacophore. Thus, oxazolidinone-containing hybrids are useful scaffolds for the development of novel anti-MRSA agents. This review covers the recent advances of oxazolidinonecontaining hybrids with anti-MRSA activity developed in the last decade to set up the direction for the design and development of oxazolidinone-containing hybrids with high efficiency and low toxicity.
Export Options
About this article
Cite this article as:
Jiang Dan , Liu Bi and Gao Tao *, Oxazolidinone-containing Hybrids with Antibacterial Activity against Methicillin-resistant Staphylococcus aureus (MRSA): A Mini-review, Current Topics in Medicinal Chemistry 2021; 21 (27) . https://dx.doi.org/10.2174/1568026620999201113104935
DOI https://dx.doi.org/10.2174/1568026620999201113104935 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
γ δ T Cells and Dendritic Cells: Close Partners and Biological Adjuvants for New Therapies
Current Molecular Medicine Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Patent Selections
Recent Patents on Anti-Infective Drug Discovery Lipids as Biomarkers of Cancer and Bacterial Infections
Current Medicinal Chemistry Clinical Development of Microbicides for the Prevention of HIV Infection
Current Pharmaceutical Design Quinolones: Action and Resistance Updated
Current Topics in Medicinal Chemistry Polysaccharides to Combat Viruses (COVID-19) and Microbes: New updates
Current Molecular Pharmacology Insights into Novel Coronavirus Disease 2019 (COVID-19): Current Understanding, Research, and Therapeutic Updates
Recent Patents on Biotechnology Determination of Human Serum α1-Acid Glycoprotein and Albumin Binding of Various Marketed and Preclinical Kinase Inhibitors
Current Medicinal Chemistry Applications of Stripping Voltammetry at Carbon Paste and Chemically Modified Carbon Paste Electrodes to Pharmaceutical Analysis
Current Pharmaceutical Analysis Analysis of Wild-Type and Gly96Ala Mutant EPSP Synthase Structures via in Silico Docking with Inhibitors and Molecular Dynamics Simulation
Current Bioactive Compounds Bridged Piperazines and Piperidines as CCR1 Antagonists with Oral Activity in Models of Arthritis and Multiple Sclerosis
Letters in Drug Design & Discovery Tumor Markers in Patients with Benign and Malignant Pulmonary Diseases; Competitive Evaluation of ProGRP, NSE and Cyfra 21-1
Recent Patents on Biomarkers Function Prediction of Hypothetical Proteins Without Sequence Similarity to Proteins of Known Function (SUPPLEMENTARY MATERIALS)
Protein & Peptide Letters Cathelicidins: Peptides with Antimicrobial, Immunomodulatory, Anti- Inflammatory, Angiogenic, Anticancer and Procancer Activities
Current Protein & Peptide Science BM 212 and its Derivatives as a New Class of Antimycobacterial Active Agents
Current Medicinal Chemistry Virtual Screening and Synthesis of Novel Antitubercular Agents Through Interaction-Based Pharmacophore and Molecular Docking Studies
Current Computer-Aided Drug Design Macrophage Targeted Cellular Carriers for Effective Delivery of Anti-Tubercular Drugs
Recent Patents on Anti-Infective Drug Discovery Design, Synthesis and Anti-tuberculosis Activity of Hydrazones and N-acylhydrazones Containing Vitamin B6 and Different Heteroaromatic Nucleus
Letters in Drug Design & Discovery